Ischemic Heart Disease,Diabetes Mellitus
Conditions
Interventions
In vildagliptin group,patients will be administered vildagliptin 100mg/day in one-year after the percutaneous coronary intervention.
In glimepiride group,patients will be administered glimepiride 1-4m
Sponsors
Center for Cardiovascular Interventions,Chiba University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who underwent stent implantation for coronary heart disease. 2) Type2 diabetes mellitus with HbA1c level of 6.0% to 9.0% (if taking a glucose-lowering medication) or 6.5% to 10% (if not currently receiving drug therapy).
Exclusion criteria
Exclusion criteria: 1)Patients with severe coronary stenosis who are eligible for IVUS. 2)Acute myocardial infarction 3)Patients who have unprotected LMT lesion. 4)Severe renal disease or/and serum creatinine level>2.0mg/dl 5)Left ventricular ejection fraction=<40% 6)Type1 diabetes mellitus 7)Allergy for antiplatelet,anticoagulant drug,dipeptidyl-peptidase4 inhibitor and sulfonylureas 8)Severe liver dysfunction 9)Pregnancy 10)Other patients judged as being inappropriate for the subjects of the study by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in coronary plaque volume | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Change in coronary plaque character by IB-IVUS (integrated backscatter intravascular ultrasound). 2)HbA1c,BS,TG,LDL-CHO,HDL-CHO. | — |
Countries
Japan
Contacts
Public ContactKeiichiro Miura
Chiba University Hospital Center for Cardiovascular Interventions
Outcome results
None listed